Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Melanoma 21Carcinoma, Renal Cell 21Neoplasms 8Lung Neoplasms 8Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Neoplasm Metastasis 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Rectal Neoplasms 5Hodgkin Disease 5Adenocarcinoma Of Esophagus 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Nasopharyngeal Carcinoma 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Anus Neoplasms 3

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2radium Ra 223 dichloride 1peposertib 1encorafenib 1cabozantinib 1binimetinib 1avelumab 1alovudine 1Surgical Procedures, Operative 1Radiosurgery 1Nivolumab 1Ipilimumab 1DNA Mismatch Repair 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Metastasis × Nivolumab × 30 days × Clear all
NCT03793166 2026-05-29

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,175 enrolled
Genitourinary

Carcinoma, Renal Cell, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡